Anti-PD-1/PD-L1 immunotherapy is a life-changing regimen for HCC patients as it substantially improves the overall survival (OS) and progression-free survival (PFS) (Hamanishi et al., 2016). Here, PDCD1 is linked to hepatocellular carcinoma.